

Key Sanochemia Group Data in T€

Performance data

	Q1	Q2	Q1-Q2	Q1-Q2	Change as %	2003/04	2002/03
	2004/05	2004/05	2004/05	2003/04		2003/04	2002/03
	Oct.04-Dec.04	Jan.05-Mar.05	Oct.04-Mar.05	Oct.03-Mar.04		Oct.03-Sep.04	Oct.02-Sep.03
Sales revenues *	7.618	7.545	15.163	12.852	18%	25.798	18.667
<i>Sales&Marketing (Human Pharmaceuticals)</i>	2.875	2.790	5.665	4.177	36%	9.758	7.773
<i>Production</i>	4.743	4.744	9.487	8.651	10%	15.982	10.893
<i>R&D</i>	0	2	2	24	-92%	58	1
<i>Reconciliation</i>	0	9	9	0	0%	0	0
EBITDA	1.799	2.400	4.199	2.342	79%	2.968	-1.148
Depreciation / amortisation	-977	-991	-1.968	-2.306	15%	-4.618	-4.126
EBIT *	822	1.409	2.231	36	6097%	-1.650	-5.274
<i>Sales&Marketing (Human Pharmaceuticals)</i>	47	294	341	-614	-	-1.654	-1.703
<i>Production</i>	1.621	2.729	4.350	3.038	43%	4.823	1.825
<i>R&D</i>	-112	-801	-913	-1.271	28%	-1.941	-2.999
<i>Reconciliation</i>	-734	-813	-1.547	-1.117	-38%	-2.878	-2.397
Financial result	840	1.172	2.012	2.036	-1%	935	2.478
Pre-tax profit / loss	1.662	2.581	4.243	2.072	105%	-716	-2.796
Profit / loss after taxes	1.107	1.830	2.937	1.151	155%	-1.858	-1.336
Earnings / losses per share	0,11	0,18	0,29	0,11	164%	-0,18	-0,13

Structural data

	2004/05	2003/04	Change as %	2003/04	2002/03
	31.03.2005	31.03.2004		30.09.2004	30.09.2003
	Balance sheet total	87.711		80.937	8%
Fixed assets	17.102	17.727	-4%	17.282	16.575
Intangible assets	17.778	17.409	2%	17.677	17.667
Shareholders' equity	56.082	56.114	0%	53.142	55.050
Equity ratio	63,9%	69,3%	-8%	71,1%	70,0%

IFRS Cash flow

	Q1-Q2	Q1-Q2	Change as %	2003/04	2002/03
	2004/05	2003/04		2003/04	2002/03
	Oct.04-Mar.05	Oct.03-Mar.04		Oct.03-Sep.04	Oct.02-Sep.03
Cash flow from operating activities	3.973	2.719	46%	5.159	-1.034
Cash flow used for investment	-1.904	-3.208	41%	-5.411	703
Cash flow from / for financing activities	1.950	1.239	57%	-593	2.256

* The figures for the previous year have been restated to reflect the new classification.

Due to the application of new IFRS guidelines certain figures may not correspond with those previously published.
Some minor changes may be due to rounding cumulative figures.